Israeli Startup Develops App To Help Prevent Premature Ejaculation

An Israeli startup has developed an app-related remedy that could prevent premature ejaculation in men.

Virility Medical, which operates within the technology incubator of NGT3 in the northern Israeli city of Nazareth, announced that it successfully completed a clinical trial in human males using a patch placed between the anus and scrotum which is then controlled by a smartphone application.

SEE ALSO: Groundbreaking Study Finds World Of Genetic Differences Between Men And Women

The application “sends a low-frequency electrical current that contracts the muscle responsible for ejaculation, and delays it,” Virility Medical said in a statement last week.

The trial, which took place at the Clinic for Sexual Dysfunction at the Rambam Medical Center in Haifa and was led by Dr. Arik Shechter and Prof. Ilan Gruenwald, was deemed successful with no immediate side effects.

According to Virility Medical, an average 3.5-fold increase in delaying ejaculation was recorded among 20 patients suffering from premature ejaculation who took part in the trial.

“An estimated 79 million men suffer from premature ejaculation in the United States and in the EU, and more than 15 million men are actively looking for a medical solution to the problem. We’re bringing a groundbreaking, effective, and simple solution, with no side effects compared to existing products on the market,” said Tal Gollan, the founder and CEO of Virility Medical.

The CEO of NGT3, a venture capital fund that invests in early-stage startups in the medical technology field, said the market potential for the solution “has a market potential significantly larger than the Viagra pill.”

“The innovative and very effective technology of Virility Medical will be a game changer, and our mission at NGT3 is to continue to advance the company at the quick rate it is has been moving,” said Zohar Gendler.. Courtesy

“The innovative and very effective technology of Virility Medical will be a game changer, and our mission at NGT3 is to continue to advance the company at the quick rate it is has been moving,” said Zohar Gendler.

Gendler said Virility Medical has so far received NIS 3 million (approximately $860,000) from NGT3 and the Israel Innovation Authority, a government-run R&D fund, and would soon embark on a second round of fundraising.

SEE ALSO: It’s Official: Prolonged Cell Phone Use Leads To Lower Sperm Count